Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib in Second-Line Chronic Phase CML
NCT01746836Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2013
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib in chronic myeloid leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Major Cytogenetic Response at 6 months and Time to Toxicity. Started Jan 2013; status: recruiting.
02
Drugs
ponatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01746836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01746836.